Thank you, Mr. Chair.
Dr. Lamarre, I'm very pleased that you are here before the committee. As I mentioned when I was inviting you, you have been a remarkable witness for this committee. What I have learned from your point of view is the idea of funding throughout the vaccine and drug development chain, which needs to provide long-term funding for all the stakeholders in all the sectors, from research to sales, to rebuild a rich, innovative, collaborative, flexible, and diversified ecosystem. You spoke about this briefly earlier.
Since the last time you appeared before this committee a year ago, do you find that the progress made by governments, and the Canadian government in particular, is satisfactory?